GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD.
The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post GSK’s triple-med COPD inhaler wins recommendation for approval in EU appeared first on MassDevice.
from MassDevice http://ift.tt/2wh6kMM
Cap comentari:
Publica un comentari a l'entrada